Navigation Links
Predicting Breast Cancer Recurrence By Understanding Gene Signature

Researchers say they have now identified a group of genes known as a gene signature, that could help single out which breast cancer patients may be at high risk for having a future cancer recurrence .//

For the study the gene expressions in 286 tumor samples from 209 lymph-node-negative breast cancer patients were examined. The patients had not received hormone or chemotherapy after their initial cancer treatment and varied in age and in their tumor sizes.

Results analyzed, after a follow-up averaging eight years, showed 93 of the women had cancer that spread to another part of their body. Through analyzing 115 of the tumors, researchers identified a 76-gene signature that could predict cancer relapse. The gene signature was tested on 171 lymph-node-negative patients in the study and it predicted (with a 93-percent sensitivity) which patients would have a cancer recurrence within five years. However the test was less accurate (with a 46-percent sensitivity) at predicting cancer recurrence beyond five years.

Since some studies identifying gene signatures for breast cancer recurrence do not identify the same groups of genes when compared, researchers say it becomes difficult to determine which gene signature test to trust. Thus in conclusion researchers say if further studies are done it could help determine better treatment plans for cancer patients .
'"/>




Page: 1

Related medicine news :

1. Predicting The Risk Of Preeclampsia During Pregnancy
2. Predicting The Risk Of A Heart Attack
3. Predicting Severity Of Appendicitis With Computed Tomography
4. Predicting The Risk Of Breast Cancer In The Future
5. Predicting The Risk Of Osteoarthritis
6. Researchers Find Mix of Biomarkers Predicting Mortality
7. Biomarkers Predicting Mortality Found Using Statistical Technique
8. HIV RNA Level Seen As Little Value In Predicting Treatment
9. Predicting the Dynamics of Clotting in Human Blood
10. Follicle Count Test as Good as Hormone Tests in Predicting Ovarian Response
11. Consensus on "Combination Therapy" for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... ... ... ProText Layouts is a set of 30 self-animating kinetic text layouts created ... video editors can create an energetic typography video with incredible ease. Utilize intuitive ... text-based videos have never been easier. , ProText Layouts includes 30 kinetic text layouts ...
(Date:4/28/2016)... ... April 28, 2016 , ... University of New England President Danielle N. ... vice president of Student Engagement. In addition to his role as director of ... areas. , “In the space of just one year Jack has distinguished himself ...
(Date:4/28/2016)... D.C., (PRWEB) , ... April 28, 2016 , ... ... systems, and the Campaign for Tobacco-Free Kids, a leading force in the fight ... promote federal, state and local policies that can help reduce tobacco use. The ...
(Date:4/28/2016)... ... 2016 , ... Horizon Blue Cross Blue Shield of New ... make transformative changes in how health care is delivered and financed in New ... breakthroughs in cellular medicine to treat disease. After accepting an invitation to speak ...
(Date:4/28/2016)... ... April 28, 2016 , ... Amada Senior Care, premier provider of ... San Antonio – its San Antonio West location. Prior to entering the senior care ... The grand opening of Amada San Antonio West will take place on Friday, April ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... NEW YORK , April 28, 2016 ... of online consumer insights on healthcare, announced today that ... in their report Cool Vendor in Life Sciences, ... , April 15, 2016.  The report focuses on life-science- ... to gain insight from patients and doctors, confirm medication ...
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company ... and vaccines for the treatment of cancer & metastatic disease, ... Growth Capital Expo to be held on May 3 ... in Las Vegas, Nevada.  The Company presentation will be ... by Dr. John N. Bonfiglio a TapImmune Board ...
Breaking Medicine Technology: